Greyledge operations are currently being led by company Founder and CEO – David Karli. He is responsible for all aspects of company development, including the integration of a strong team of professionals to support Greyledge’s innovative approach to regenerative medicine.
After attending medical school at the University of Maryland, Dr. Karli completed his residency in Physical Medicine and Rehabilitation at Harvard Medical School. Subsequently, he joined the faculty at Harvard, serving as an Attending Physician with the Department of PM&R at Spaulding Rehabilitation Hospital, as well as working in the Department of Orthopedic Surgery at Mass General Hospital.
After joining the Steadman Clinic in 2003, Dr. Karli began to adopt the use of autologous-based therapies that were emerging in the field of regenerative medicine. He has continued to lead the effort required to refine the practice of regenerative medicine, and has published pivotal clinical results and lectured extensively. His practice has grown substantially and includes treating elite-level and professional athletes. As a result, Dr. Karli has been featured in high-level media publications such as the Wall Street Journal, New York Times, ESPN Magazine and Denver Magazine.
Dr. Karli recognized early on that understanding the composition of regenerative biologic preparations used in treating his patients would be critical to refining his practice of medicine. He also realized that a “one size fits all” approach to creating the therapeutic preparations wouldn’t meet the need for an evidence-based, precision medicine approach. As a result, he founded Greyledge. In support of his concept for regenerative medicine, he completed the COLA Laboratory Director training course, and obtained his MBA (Daniels College of Business, University of Denver).
Greyledge has achieved sustained profitability and is ready for scalable expansion. Dr. Karli is positioning the company to maintain its unique technology platform offering by tracking regulatory activity, advancing biologic sample analytics and quality measures, and creating protocols that allow for customization of patient biologic preparations.